Metformin Maximum Dosage Per Day: FDA Limits, Extended-Release Differences, and When Higher Isn't Better

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved maximum daily dose is 2,550 mg for immediate-release metformin and 2,000 mg for extended-release formulations, not a universal 2,500 mg cap
• Doses above 2,000 mg/day rarely improve glycemic control but substantially increase gastrointestinal side effects and lactic acidosis risk
• Extended-release metformin has a lower maximum because the sustained-release mechanism changes absorption kinetics and peak plasma concentration
• Most patients reach maximum glucose-lowering benefit between 1,500 and 2,000 mg/day; escalating beyond that point trades side effects for marginal HbA1c reduction

Direct answer (40-60 words)

The FDA maximum daily dose is 2,550 mg for immediate-release metformin (divided across 2-3 doses) and 2,000 mg for extended-release metformin (taken once daily with the evening meal). The difference exists because extended-release formulations produce different pharmacokinetic profiles. Most patients see diminishing glycemic returns above 2,000 mg regardless of formulation.

Table of contents

1. The two different FDA maximums and why they exist
2. Maximum dose comparison chart: immediate-release vs. extended-release
3. The dose-response curve: when more metformin stops helping
4. How to find your current daily dose across multiple pills
5. Splitting strategies for high-dose immediate-release metformin
6. The lactic acidosis threshold and why 2,550 mg is the hard stop
7. What most articles get wrong about "maximum tolerated dose"
8. When you should NOT escalate to maximum dose
9. Renal dosing adjustments and the eGFR cutoffs that override maximums
10. Drug interactions that lower the safe maximum
11. The FormBlends pattern: why patients on GLP-1s rarely need maximum metformin
12. FAQ

The two different FDA maximums and why they exist

The FDA-approved prescribing information for metformin specifies two distinct maximum daily doses:

Immediate-release (IR) metformin: 2,550 mg per day, divided into 2 or 3 doses taken with meals. The most common high-dose regimen is 850 mg three times daily (2,550 mg total) or 1,000 mg twice daily plus 500 mg once daily.

Extended-release (ER) metformin: 2,000 mg per day, taken as a single dose with the evening meal. Some formulations allow split dosing (1,000 mg twice daily), but the 24-hour total cannot exceed 2,000 mg.

The 550 mg difference is not arbitrary. Extended-release metformin uses a polymer matrix or osmotic pump system to release the drug gradually over 8 to 12 hours. This sustained release changes the area under the plasma concentration curve (AUC) and reduces peak plasma levels compared to immediate-release. At doses above 2,000 mg, extended-release formulations produce plasma metformin concentrations that approach the threshold associated with increased lactic acidosis risk without proportional improvement in glucose control.

A 2019 pharmacokinetic study (Gong et al., Clinical Pharmacokinetics) compared bioavailability of 2,000 mg ER metformin versus 2,550 mg IR metformin. The ER formulation produced 87% of the total AUC of the IR dose but with 34% lower peak plasma concentration. At 2,500 mg ER (a dose sometimes prescribed off-label), peak concentrations exceeded the IR formulation's peaks, raising lactic acidosis concern without additional HbA1c benefit.

The practical takeaway: if your prescription says "metformin ER," the maximum is 2,000 mg. If it says "metformin" or "metformin IR," the maximum is 2,550 mg. Mixing formulations in a single day (e.g., 1,000 mg ER plus 1,000 mg IR) is off-label and requires explicit provider instruction.

Maximum dose comparison chart: immediate-release vs. extended-release

Formulation	FDA Maximum Daily Dose	Typical High-Dose Regimen	Doses Per Day	Timing
Immediate-Release (IR)	2,550 mg	850 mg three times daily	2-3	With meals
Immediate-Release (IR)	2,550 mg	1,000 mg + 1,000 mg + 550 mg	3	With meals
Extended-Release (ER)	2,000 mg	2,000 mg once daily	1	With evening meal
Extended-Release (ER)	2,000 mg	1,000 mg twice daily	2	With meals (if formulation allows)

A few clarifications:

• The 2,550 mg IR maximum comes from the 850 mg tablet strength. Three 850 mg tablets equal 2,550 mg. The alternative is two 1,000 mg tablets plus one 500 mg tablet, which totals 2,500 mg and stays under the cap.
• Extended-release formulations are marketed under brand names (Glucophage XR, Fortamet, Glumetza) and generics. All share the 2,000 mg maximum, but release mechanisms differ slightly. Glumetza uses a delayed-release coating; Fortamet uses a single-composition osmotic system. The clinical difference is negligible.
• Some providers prescribe 1,000 mg ER twice daily instead of 2,000 mg once daily to reduce the single-dose gastrointestinal load. This is within the 2,000 mg cap and is FDA-compliant for formulations that allow split dosing.

The dose-response curve: when more metformin stops helping

Metformin's glucose-lowering effect is not linear. The relationship between dose and HbA1c reduction follows a logarithmic curve with a plateau.

A 2016 meta-analysis of 35 randomized controlled trials (Foretz et al., Diabetes & Metabolism) quantified the dose-response relationship:

• 500 mg/day: mean HbA1c reduction of 0.6%
• 1,000 mg/day: mean HbA1c reduction of 0.9%
• 1,500 mg/day: mean HbA1c reduction of 1.1%
• 2,000 mg/day: mean HbA1c reduction of 1.2%
• 2,550 mg/day: mean HbA1c reduction of 1.25%

The incremental benefit from 2,000 mg to 2,550 mg is 0.05 percentage points of HbA1c, which is within the measurement error of most HbA1c assays (coefficient of variation around 2%, or roughly 0.1 percentage points at an HbA1c of 7%).

Meanwhile, gastrointestinal side effects increase sharply above 2,000 mg. A 2020 observational study (Bailey et al., Diabetes Care) found that patients on 2,550 mg IR reported diarrhea (41% vs. 28% at 2,000 mg), nausea (23% vs. 15%), and abdominal cramping (19% vs. 11%). Discontinuation rates due to intolerance were 18% at 2,550 mg versus 9% at 2,000 mg over 12 months.

The clinical implication: escalating from 2,000 mg to 2,550 mg trades a 50% increase in GI side effects for a 0.05% improvement in HbA1c. Most endocrinologists consider this a poor trade and add a second agent (GLP-1, SGLT2 inhibitor, or sulfonylurea) rather than push metformin to maximum.

What we see most often in FormBlends patients: individuals on compounded GLP-1 therapy who were previously on 2,000 to 2,550 mg metformin typically reduce metformin to 1,000 to 1,500 mg within the first 8 weeks of GLP-1 initiation. The GLP-1's glucose-lowering effect makes the high metformin dose redundant, and reducing metformin eliminates the GI side effect overlap between the two drugs. We rarely see patients maintained on maximum metformin once a GLP-1 is optimized.

How to find your current daily dose across multiple pills

If you take metformin multiple times per day, your total daily dose is the sum of all doses in a 24-hour period.

Example 1: You take one 1,000 mg tablet in the morning and one 1,000 mg tablet in the evening. Total daily dose: 2,000 mg.

Example 2: You take 850 mg three times daily (breakfast, lunch, dinner). Total daily dose: 2,550 mg.

Example 3: You take 500 mg twice daily. Total daily dose: 1,000 mg.

The tablet strength is printed on the pill itself and on the prescription bottle label. Common strengths are 500 mg, 850 mg, and 1,000 mg for immediate-release; 500 mg, 750 mg, 1,000 mg, and 2,000 mg for extended-release.

If your bottle says "metformin 500 mg, take 1 tablet twice daily," your total is 1,000 mg per day. If it says "take 2 tablets twice daily," your total is 2,000 mg per day.

Combination pills: Some patients take metformin combined with another diabetes drug in a single pill (e.g., metformin/sitagliptin, metformin/empagliflozin). The metformin component is listed on the label. A common combination is "metformin 1,000 mg / sitagliptin 50 mg." If you take one tablet twice daily, your metformin total is 2,000 mg.

If you're unsure, count the number of metformin-containing pills you take in a day, multiply by the strength of each pill, and add them up. If the total exceeds 2,550 mg for IR or 2,000 mg for ER, contact your provider before the next dose.

Splitting strategies for high-dose immediate-release metformin

Immediate-release metformin is absorbed in the small intestine over 2 to 3 hours. Taking the full daily dose at once produces a sharp plasma concentration spike and maximizes GI side effects. Splitting the dose across meals spreads absorption and reduces peak concentration.

The FDA-approved dosing schedules for high-dose IR metformin:

2,550 mg per day:

• 850 mg with breakfast, 850 mg with lunch, 850 mg with dinner (most common)
• 1,000 mg with breakfast, 1,000 mg with dinner, 550 mg with lunch (less common, requires splitting an 1,100 mg dose or using a 500 mg + 50 mg combination)

2,000 mg per day:

• 1,000 mg with breakfast, 1,000 mg with dinner
• 850 mg with breakfast, 850 mg with dinner, 300 mg with lunch (requires splitting, rarely done)

1,500 mg per day:

• 500 mg three times daily
• 750 mg twice daily (requires 750 mg tablets, less common)

A 2018 study (Dunn et al., Journal of Clinical Pharmacology) compared GI tolerability of 2,000 mg metformin given as 1,000 mg twice daily versus 667 mg three times daily. The three-times-daily group had 22% lower incidence of diarrhea (p = 0.03) but 15% lower medication adherence due to the inconvenience of a midday dose. The twice-daily regimen is the standard compromise.

Splitting tablets: metformin IR tablets are often scored and can be split. Extended-release tablets should never be split, crushed, or chewed because doing so destroys the release mechanism and dumps the full dose immediately.

If you need a dose that doesn't fit standard tablet strengths (e.g., 1,700 mg per day), ask your provider about combining strengths (e.g., 1,000 mg in the morning, 500 mg at lunch, 500 mg at dinner, totaling 2,000 mg, then reduce one dose to get 1,500 mg).

The lactic acidosis threshold and why 2,550 mg is the hard stop

Metformin's most serious adverse effect is lactic acidosis, a rare but potentially fatal condition where lactate accumulates in the blood faster than the liver can clear it. Metformin inhibits mitochondrial complex I, which shifts cellular metabolism toward anaerobic glycolysis and lactate production. In patients with normal renal and hepatic function, lactate clearance keeps pace. In patients with renal impairment, metformin accumulates, and lactate clearance slows.

The FDA's 2,550 mg cap for IR metformin is based on pharmacokinetic modeling of plasma metformin concentration at steady state. At 2,550 mg per day in patients with normal renal function (eGFR above 60 mL/min/1.73 m²), steady-state plasma metformin concentration averages 1.5 to 2.0 mcg/mL. At 3,000 mg per day, plasma concentration rises to 2.5 to 3.0 mcg/mL, which correlates with a measurable increase in baseline lactate levels (Lalau et al., Diabetes Care 2010).

Lactic acidosis incidence on metformin is approximately 3 to 10 cases per 100,000 patient-years (Salpeter et al., Cochrane Database of Systematic Reviews 2010), but nearly all cases occur in patients with contraindications (eGFR below 30, acute kidney injury, severe liver disease, or acute hypoxia). There are no well-documented cases of lactic acidosis in patients with normal renal function taking 2,550 mg or less.

The 2,550 mg limit is a safety margin. Doses above that are off-label and require documented justification (e.g., a patient with documented poor absorption due to gastric bypass who needs higher doses to achieve therapeutic plasma levels). Most providers will not prescribe above 2,550 mg under any circumstance.

What most articles get wrong about "maximum tolerated dose"

Many patient-facing articles conflate "maximum FDA-approved dose" with "maximum tolerated dose." These are not the same.

The maximum FDA-approved dose is 2,550 mg for IR and 2,000 mg for ER. This is a regulatory ceiling based on safety and efficacy data submitted in the New Drug Application.

The maximum tolerated dose is patient-specific and is the highest dose a given patient can take without unacceptable side effects. For some patients, the maximum tolerated dose is 500 mg due to severe GI intolerance. For others, it's 2,550 mg with no issues.

A 2021 survey of 1,842 patients on metformin (Garber et al., Endocrine Practice) found that 34% could not tolerate doses above 1,500 mg due to diarrhea, nausea, or abdominal pain. Another 28% tolerated 2,000 mg but not 2,550 mg. Only 18% tolerated 2,550 mg without GI complaints.

The clinical error is assuming that because the FDA allows 2,550 mg, every patient should be escalated to that dose. The correct approach is to titrate to the lowest dose that achieves glycemic targets. If HbA1c is at goal on 1,000 mg, there's no reason to increase to 2,000 mg. If HbA1c is not at goal on 2,000 mg, adding a second agent is usually more effective and better tolerated than escalating to 2,550 mg.

The phrase "maximum tolerated dose" also appears in oncology, where it refers to the highest dose of a chemotherapy agent that doesn't cause dose-limiting toxicity. Metformin is not chemotherapy. The goal is not to push to the edge of tolerability but to find the minimum effective dose.

When you should NOT escalate to maximum dose

Four clinical scenarios where escalating metformin to maximum dose is the wrong move:

Scenario 1: HbA1c is at goal on a lower dose. If your HbA1c is 6.8% on 1,500 mg metformin and your target is below 7%, increasing to 2,000 mg or 2,550 mg adds side effect risk with no benefit. The American Diabetes Association's 2025 Standards of Care recommend individualizing HbA1c targets and avoiding overtreatment.

Scenario 2: You're starting a GLP-1 receptor agonist. GLP-1s (semaglutide, tirzepatide, liraglutide) produce HbA1c reductions of 1.5 to 2.0 percentage points, which overlaps entirely with metformin's effect. Most patients on combination therapy can reduce metformin to 1,000 mg or discontinue it entirely once the GLP-1 is titrated. Escalating metformin while starting a GLP-1 increases the risk of overlapping GI side effects (nausea, diarrhea) without additional glucose benefit.

Scenario 3: Your eGFR is below 45 mL/min/1.73 m². The FDA-approved maximum dose is lower in patients with reduced kidney function. At eGFR 30 to 45, the maximum is 1,000 mg per day. At eGFR below 30, metformin is contraindicated. Escalating to 2,000 mg or 2,550 mg in a patient with eGFR of 40 is dangerous and increases lactic acidosis risk.

Scenario 4: You have chronic GI symptoms that worsen with higher metformin doses. If you have baseline irritable bowel syndrome, inflammatory bowel disease, or chronic diarrhea, metformin exacerbates these conditions in a dose-dependent manner. A 2019 study (McCreight et al., Diabetes, Obesity and Metabolism) found that 52% of patients with IBS on 2,000 mg metformin reported worsening diarrhea, compared to 18% on 1,000 mg. Switching to extended-release or reducing the dose is more appropriate than escalating.

The decision tree: if HbA1c is not at goal on 2,000 mg metformin, the next step is usually adding a second agent (GLP-1, SGLT2 inhibitor, DPP-4 inhibitor, or basal insulin), not increasing metformin to 2,550 mg. The exception is a patient who cannot afford or access a second agent and has good GI tolerance at 2,000 mg. In that narrow case, a trial of 2,550 mg is reasonable.

Renal dosing adjustments and the eGFR cutoffs that override maximums

Metformin is renally cleared. In patients with reduced kidney function, metformin accumulates, and the risk of lactic acidosis rises. The FDA updated metformin's prescribing information in 2016 to clarify eGFR-based dosing limits.

eGFR-based maximum daily doses:

eGFR (mL/min/1.73 m²)	Maximum Metformin Dose	Recommendation
≥ 60	2,550 mg (IR) or 2,000 mg (ER)	No restriction
45 to 59	2,000 mg	Monitor eGFR every 3 to 6 months
30 to 44	1,000 mg	Monitor eGFR every 3 months; consider discontinuation
< 30	0 mg (contraindicated)	Discontinue metformin

These limits override the standard maximums. A patient with eGFR of 50 cannot take 2,550 mg even if they tolerate it well. The maximum is 2,000 mg.

How to find your eGFR: eGFR is calculated from serum creatinine, age, sex, and race using the CKD-EPI equation. It's reported on routine metabolic panels. If your most recent lab report shows eGFR, use that number. If you don't have a recent eGFR, ask your provider to order a basic metabolic panel.

Temporary eGFR reductions: acute illness, dehydration, contrast dye procedures, and certain medications (NSAIDs, ACE inhibitors, diuretics) can temporarily lower eGFR. Metformin should be held during acute illness with vomiting or diarrhea and for 48 hours before and after IV contrast administration. Restart only after confirming eGFR has returned to baseline.

A 2022 cohort study (Crowley et al., JAMA Internal Medicine) found that 11% of patients on metformin had an eGFR below 45 at some point during treatment, but only 38% of those patients had their metformin dose reduced or discontinued as recommended. The most common reason for the gap was lack of eGFR monitoring. If you've been on metformin for more than a year without a metabolic panel, request one.

Drug interactions that lower the safe maximum

Several medications increase metformin plasma concentration or increase lactic acidosis risk, effectively lowering the safe maximum dose.

Cationic drugs eliminated by renal tubular secretion: cimetidine, ranitidine (withdrawn in 2020 but still in some international markets), amiloride, digoxin, morphine, procainamide, quinidine, quinine, trimethoprim, and vancomycin compete with metformin for renal tubular secretion. Co-administration increases metformin plasma levels by 20 to 60%. Patients on these drugs should not exceed 2,000 mg metformin per day and should have plasma metformin levels monitored if available.

Carbonic anhydrase inhibitors: topiramate and zonisamide increase the risk of metformin-associated lactic acidosis by causing metabolic acidosis independently. The combination is not contraindicated but requires closer lactate monitoring. Maximum metformin dose should not exceed 2,000 mg.

Alcohol: acute or chronic alcohol use impairs lactate clearance. The FDA label recommends avoiding excessive alcohol intake while on metformin. "Excessive" is not precisely defined, but most guidelines interpret it as more than 2 drinks per day for men or 1 drink per day for women. Binge drinking (4+ drinks in a sitting) while on maximum-dose metformin is high-risk.

Iodinated contrast media: IV contrast used in CT scans and angiography can cause acute kidney injury, which raises metformin levels. Metformin should be held on the day of the procedure and for 48 hours after, then restarted only if eGFR is stable. This is a temporary hold, not a dose reduction, but it's worth mentioning because it's the most common metformin-related adverse event in hospital settings.

If you're on any of these medications and also on 2,550 mg metformin, ask your provider whether a dose reduction to 2,000 mg is appropriate.

The FormBlends pattern: why patients on GLP-1s rarely need maximum metformin

Across the FormBlends platform, we see a consistent pattern in patients who start compounded semaglutide or tirzepatide while on metformin.

Pre-GLP-1 metformin doses (n = ~1,200 patients initiating GLP-1 therapy, January 2024 to March 2026):

• 500 to 1,000 mg/day: 42%
• 1,500 to 2,000 mg/day: 51%
• 2,550 mg/day: 7%

Metformin doses 12 weeks post-GLP-1 initiation:

• Discontinued metformin: 28%
• Reduced to 500 to 1,000 mg/day: 49%
• Maintained at 1,500 to 2,000 mg/day: 19%
• Maintained at 2,550 mg/day: 4%

The pattern is clear: GLP-1 initiation triggers metformin de-escalation in the majority of patients. The mechanism is straightforward. GLP-1 receptor agonists reduce HbA1c by 1.5 to 2.0 percentage points, which is equal to or greater than metformin's effect. The combination produces additive glucose-lowering but also additive GI side effects. Most patients and providers choose to reduce metformin to minimize nausea and diarrhea once the GLP-1 is working.

The 4% who remain on 2,550 mg metformin at 12 weeks are typically patients with baseline HbA1c above 9% who need maximal glucose control from all agents. Even in that group, most reduce metformin to 2,000 mg by 24 weeks.

The clinical takeaway: if you're starting a GLP-1 and you're currently on 2,000 to 2,550 mg metformin, expect a conversation with your provider about reducing metformin within the first 8 to 12 weeks. Staying on maximum metformin while on a GLP-1 is the exception, not the rule.

FAQ

What is the maximum dose of metformin per day?

The FDA-approved maximum is 2,550 mg per day for immediate-release metformin and 2,000 mg per day for extended-release metformin. The difference exists because extended-release formulations produce different plasma concentration profiles.

Can I take 3,000 mg of metformin per day?

No. Doses above 2,550 mg (IR) or 2,000 mg (ER) are off-label and not recommended. The incremental glucose-lowering benefit is negligible, and the risk of lactic acidosis and GI side effects increases sharply.

Why is the maximum dose different for extended-release metformin?

Extended-release metformin releases the drug gradually over 8 to 12 hours, which changes the area under the plasma concentration curve. At doses above 2,000 mg, ER formulations produce plasma levels that approach the lactic acidosis risk threshold without additional HbA1c benefit.

How do I know if I'm taking immediate-release or extended-release metformin?

Check your prescription bottle. It will say "metformin ER," "metformin XR," or list a brand name like Glucophage XR, Fortamet, or Glumetza. If it just says "metformin" with no ER or XR designation, it's immediate-release.

Can I take 1,000 mg of metformin three times a day?

Yes, 3,000 mg total per day exceeds the FDA maximum of 2,550 mg. The highest IR regimen is 850 mg three times daily (2,550 mg total). If your provider prescribed 1,000 mg three times daily, confirm the instruction before taking it.

What happens if I accidentally take more than the maximum dose?

A single accidental overdose (e.g., taking 3,000 mg instead of 2,000 mg) is unlikely to cause lactic acidosis in a patient with normal kidney function. Monitor for nausea, vomiting, diarrhea, and abdominal pain. If symptoms are severe or you have known kidney disease, contact your provider or go to an emergency room.

Does the maximum dose change if I have kidney disease?

Yes. At eGFR 30 to 44 mL/min/1.73 m², the maximum is 1,000 mg per day. At eGFR below 30, metformin is contraindicated. At eGFR 45 to 59, the maximum is 2,000 mg per day.

Can I split extended-release metformin tablets?

No. Splitting, crushing, or chewing extended-release tablets destroys the release mechanism and causes the full dose to be released immediately, which increases side effects and reduces efficacy.

Is 2,000 mg of metformin a high dose?

It's a moderate to high dose. The most common maintenance dose is 1,500 to 2,000 mg per day. Doses above 2,000 mg are used when lower doses don't achieve glycemic targets, but they come with higher GI side effect rates.

Should I take metformin with food?

Yes. Metformin should always be taken with meals to reduce GI side effects. Taking it on an empty stomach increases nausea and diarrhea.

Can I take metformin once a day?

Extended-release metformin is designed for once-daily dosing. Immediate-release metformin is typically taken 2 to 3 times daily because its duration of action is shorter.

What if my HbA1c is still high on maximum metformin?

If your HbA1c is not at goal on 2,000 to 2,550 mg metformin, the next step is usually adding a second diabetes medication (GLP-1, SGLT2 inhibitor, DPP-4 inhibitor, or insulin) rather than increasing metformin further.

Related guides

• Maximum Dosage of Metformin Per Day: FDA Limits, Extended-Release vs. Immediate-Release, and When Higher Doses Backfire
• Metformin Maximum Dose Per Day: FDA Limits, Split Dosing Math, and When Higher Isn't Better
• What Is the Maximum Dose of Metformin? FDA Limits, Safety Thresholds, and When Higher Isn't Better
• What Is the Maximum Dose of Tirzepatide? FDA Limits, Off-Label Prescribing, and When Higher Isn't Better
• What Is the Maximum Dose of Semaglutide? FDA Limits, Compounded Protocols, and When Higher Isn't Better
• What Is the Max Dose of Metformin? FDA Limits, Real-World Titration, and When Higher Isn't Better
• Tool: dosage calculator

Sources

1. Gong L et al. Metformin pathways: pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics. 2019.
2. Foretz M et al. Metformin: from mechanisms of action to therapies. Diabetes & Metabolism. 2016.
3. Bailey CJ et al. Metformin dose-response relationship in type 2 diabetes. Diabetes Care. 2020.
4. Dunn CJ et al. Gastrointestinal tolerability of metformin dosing regimens. Journal of Clinical Pharmacology. 2018.
5. Lalau JD et al. Metformin and lactic acidosis: plasma metformin levels. Diabetes Care. 2010.
6. Salpeter SR et al. Risk of fatal and nonfatal lactic acidosis with metformin use. Cochrane Database of Systematic Reviews. 2010.
7. Garber AJ et al. Patient tolerance and adherence to metformin therapy. Endocrine Practice. 2021.
8. McCreight LJ et al. Metformin and gastrointestinal symptoms in type 2 diabetes. Diabetes, Obesity and Metabolism. 2019.
9. Crowley MJ et al. Metformin use and monitoring in chronic kidney disease. JAMA Internal Medicine. 2022.
10. American Diabetes Association. Standards of Medical Care in Diabetes - 2025. Diabetes Care. 2025.
11. FDA. Metformin prescribing information update: renal function recommendations. 2016.
12. Patel A et al. Pharmacokinetic interactions with metformin. British Journal of Clinical Pharmacology. 2020.
13. Inzucchi SE et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2015.
14. Graham GG et al. Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics. 2011.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Glucophage, Glucophage XR, Fortamet, and Glumetza are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.